CV Sciences (CVSI) AI Stock Analysis

• Market Cap: $5.87M
• Dividend Yield: N/A
• Average Volume (3M): 246.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.49
• Revenue Growth: -8.04%
• EPS Growth: 47.02%
• Country: US
• Employees: 47
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 184,263,660
• 10 Day Avg. Volume: 158,629
• 30 Day Avg. Volume: 246,649
• PEG Ratio: 0.01
• Price to Book (P/B): 3.31
• Price to Sales (P/S): 0.38
• P/FCF Ratio: -6.75
• Enterprise Value/Market Cap: 1.30
• Enterprise Value/Revenue: 0.69
• Enterprise Value/Gross Profit: 1.13
• Enterprise Value/Ebitda: -8.74
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $0.00 ▼(-100.00% Downside)

CV Sciences faces significant financial challenges, with declining revenues and negative profit margins being the most critical factors. Technical analysis indicates bearish momentum, further weighing on the stock. While the earnings call provided some positive insights, such as improved gross margins and cost efficiencies, the overall financial health remains weak. The valuation is unattractive due to ongoing losses and lack of dividends.

Positive Factors

Gross Margin Improvement

The improvement in gross margin to 50.9% indicates better cost management and pricing power, enhancing profitability potential.

New Product Development

Successful new product development diversifies revenue streams and strengthens market position, supporting long-term growth.

Strategic M&A Integration

The acquisition of Elevated Softgels enhances manufacturing capabilities, leading to cost efficiencies and improved margins.

Negative Factors

Revenue Decline

Declining revenue reflects challenges in maintaining sales volume, potentially impacting long-term financial health.

Regulatory Challenges

Ongoing regulatory challenges can hinder market expansion and increase compliance costs, affecting future growth.

Cash Flow Issues

Persistent negative cash flow from operations indicates difficulties in generating sufficient cash, limiting financial flexibility.

CV Sciences Business Overview & Revenue Model

Company Description

CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

How the Company Makes Money

CV Sciences generates revenue through multiple streams, primarily by selling its consumer products under the brand name PlusCBD Oil. This includes a variety of CBD-infused dietary supplements, oils, and topical products which are sold through various channels such as retail stores, e-commerce platforms, and direct-to-consumer sales. Additionally, CV Sciences is engaged in the development of pharmaceutical products, particularly focusing on prescription medications that utilize CBD for therapeutic purposes. The company benefits from strategic partnerships with retailers and health product distributors, which help expand its market reach. Furthermore, the growing consumer interest in CBD products and the increasing legalization of hemp-derived products across various jurisdictions contribute to the company's revenue growth.

CV Sciences Financial Statement Overview

Summary

CV Sciences is facing significant financial challenges, with declining revenues, negative profit margins, and cash flow issues. The balance sheet shows high leverage and low equity, posing potential financial stability risks. Overall, the company needs strategic improvements to return to profitability and improve cash flows.

Income Statement

The company has faced a declining revenue trend over the years, with a notable drop from 2019 to 2024. Gross profit margins have decreased significantly, indicating cost pressure. The EBIT and net profit margins are negative, reflecting operational inefficiencies and consistent net losses.

Balance Sheet

The company exhibits a high debt-to-equity ratio, indicating potential leverage risks. The equity ratio is low, highlighting limited funding from shareholders relative to total assets. However, there has been a reduction in total liabilities over time, which is a positive sign.

Cash Flow

Cash flow from operations has been consistently negative, pointing to cash generation challenges. Free cash flow is also negative, indicating a lack of surplus cash after capital expenditures. The operating cash flow to net income ratio suggests operational struggles.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.11M	15.71M	16.00M	16.20M	20.05M	24.43M
Gross Profit	6.76M	7.17M	7.08M	5.55M	8.62M	11.01M
EBITDA	-873.00K	-1.86M	3.85M	-5.66M	-14.00M	-21.72M
Net Income	-1.48M	-2.39M	3.10M	-8.21M	-15.55M	-22.28M
Balance Sheet
Total Assets	7.00M	7.93M	26.35M	12.74M	18.07M	30.63M
Cash, Cash Equivalents and Short-Term Investments	381.00K	454.00K	1.32M	611.00K	1.38M	4.02M
Total Debt	860.00K	779.00K	442.00K	1.53M	922.00K	7.77M
Total Liabilities	5.46M	6.13M	23.44M	13.51M	14.52M	19.41M
Stockholders Equity	1.54M	1.79M	2.90M	-777.00K	3.54M	11.21M
Cash Flow
Free Cash Flow	-65.00K	-879.00K	2.25M	-1.89M	-7.52M	-8.36M
Operating Cash Flow	42.00K	-861.00K	2.25M	-1.89M	-7.49M	-7.30M
Investing Cash Flow	-122.00K	-28.00K	-156.00K	0.00	-35.00K	-1.06M
Financing Cash Flow	-256.00K	32.00K	-1.39M	1.12M	4.37M	3.27M

CV Sciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVSI, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 28.02 is Positive, neither overbought nor oversold. The STOCH value of 111.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CVSI.

CV Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CVSI	42 Neutral	$5.87M	-3.65	-79.25%	―	-8.04%	47.02%
IMCC	42 Neutral	$6.72M	-2.36	-93.87%	―	-0.74%	81.49%
FLGC	40 Neutral	$6.77M	-0.23	-37.38%	―	-22.60%	53.82%
YCBD	40 Underperform	$7.21M	-0.13	-33.13%	―	-7.80%	90.17%
IXHL	39 Underperform	$122.46M	―	-114.52%	―	-86.05%	24.17%
COSM	38 Underperform	$20.93M	-0.68	-63.82%	―	―	―

CV Sciences Corporate Events

CV Sciences Reports Q3 2025 Financial Results

CV Sciences, Inc. is a consumer wellness company that specializes in hemp extracts and other science-backed, natural ingredients, operating primarily in the nutraceuticals and plant-based foods sector. The company is known for its +PlusCBD™ branded products, which are top-selling in the natural products market.

CV Sciences Reports Q3 2025 Financial Results

On November 13, 2025, CV Sciences reported its financial results for the third quarter of 2025, showing a revenue of $3.3 million, a decline from the previous year due to lower sales volume and regulatory challenges. Despite the revenue drop, the company maintained a healthy gross margin of 48.5% and introduced new products, aiming for organic growth and strategic M&A opportunities to enhance revenue and shareholder value. The company also addressed recent legislative changes affecting the hemp industry, expressing disappointment but seeing an opportunity to influence future regulations.

CV Sciences Secures $600,000 Promissory Note Agreement

On October 6, 2025, CV Sciences, Inc. entered into a note purchase agreement with an institutional investor, resulting in the issuance of a secured promissory note worth $600,000. The transaction, which closed on October 7, 2025, provided the company with net proceeds of $300,000 after deductions. The note is secured by the company’s assets and intellectual property, with repayment terms set to begin in April 2026 and a maturity date in April 2027. The agreement includes provisions for events of default, which could lead to increased liabilities for the company.

CV Sciences Amends Note Purchase Agreement

On February 12, 2025, CV Sciences, Inc. entered into a Note Purchase Agreement with an institutional investor, issuing a Secured Promissory Note for $1,600,000, with a $400,000 discount resulting in $1,200,000 received by the company. On September 12, 2025, the agreement was amended to extend the maturity date to February 12, 2027, adjust the monthly redemption amounts, and provide the investor with $150,000 in cash, maintaining the original terms otherwise.

CV Sciences’ Earnings Call: Progress Amid Challenges

CV Sciences’ latest earnings call painted a picture of both progress and challenges. The company reported significant improvements in gross margin, cash flow, and cost efficiency, alongside successful new product developments and strategic M&A integration. However, challenges such as revenue decline, regulatory issues, and a decrease in B2C revenue were noted. Despite these hurdles, the company’s positive adjusted EBITDA and improved financial metrics demonstrate progress towards profitability.